Highlights of This Issue 6081

SPECIAL FEATURES

CCR Translations

6083

Real-time Pathology to Guide Breast Surgery: Seeing Alone Is Not Believing
Irving J. Bigio
See article p. 6315

6086

Regulatory T Cells Move in When Gliomas Say "I DO"
Bryan D. Choi, Peter E. Fecci, and John H. Sampson
See article p. 6110

Molecular Pathways

6089

Molecular Pathways: The Metabolic Regulator Estrogen-Related Receptor α as a Therapeutic Target in Cancer
Ching-yi Chang and Donald P. McDonnell

6096

Molecular Pathways: Regulation of Metabolism by RB
Brian F. Clem and Jason Chesney

Review

6101

Accelerating Cancer Therapy Development: The Importance of Combination Strategies and Collaboration. Summary of an Institute of Medicine Workshop

6109

Quantitative Immunofluorescence Reveals the Signature of Active B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

6114

Expression Profiling of Archival Tumors for Long-term Health Studies
Levi Waldron, Shuji Ogino, Yujin Hoshida, Koari Shimla, Amy E. McCar, Reed, Peter T. Simpson, Yoshifumi Baba, Katsuhiko Nosho, Nicola Segata, Ana Cristina Vargas, Margaret C. Cummings, Sunil R. Lakhani, Gregory J. Kirkner, Edward Giovannucci, John Quackenbush, Todd R. Golub, Charles S. Fuchs, Giovanni Parmigiani, and Curtis Huttenhower

6122

Decreased NK Cells in Patients with Head and Neck Cancer Determined in Archival DNA

6136

Stemness of B-cell Progenitors in Multiple Myeloma Bone Marrow
Kelly Boucher, Nancy Parquet, Raymond Widen, Kenneth Shain, Rachid Baz, Melissa Alshina, John Koomen, Claudio Anasetti, William Dalton, and Lia E. Perez

6147

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
Snjezana Dogan, Ronglai Shen, Daphne C. Ang, Melissa L. Johnson, Sandra P. D’Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Biely, Mark G. Kris, Maureen F. Zakowski, and Marc Ladanyi

6148

Establishment and Characterization of Novel Cell Lines from Sinonasal Undifferentiated Carcinoma
Yoko Takahashi, Michael E. Kupferman, Diana Bell, Tilahun Jiffar, June Goo Lee, Tong-Xin Xie, Ning-Wei Li, Mei Zhao, Mitchell J. Frederick, Alexander Gelbard, Jeffrey N. Myers, and Ehab Y. Hanna

HUMAN CANCER BIOLOGY

6110

IDO Expression in Brain Tumors Increases the Recruitment of Regulatory T Cells and Negatively Impacts Survival
Derek A. Wainwright, Irina V. Balyasnikova, Alan L. Chang, Atique U. Ahmed, Kyung-Sub Moon, Brenda Auffinger, Alex L. Tobias, Yu Han, and Maciej S. Lesniak
See commentary p. 6086

6122
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6199</td>
<td>Proliferation in the Normal FTE Is a Hallmark of the Follicular Phase, Not BRCA Mutation Status</td>
<td>Sophia H.L. George, Anca Milea, and Patricia A. Shaw</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: PRECLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>6208</td>
<td>Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies</td>
<td>Eliane Fischer, Krishna Chaitanya, Thomas Wiest, Andreas Wade, Andrew M. Scott, Maries van den Broek, Roger Schibli, Stefan Bauer, and Christoph Renner</td>
</tr>
<tr>
<td>6219</td>
<td>Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK-Positive Non-Small Cell Lung Cancer</td>
<td>Junko Tanizaki, Isamu Okamoto, Takafumi Okabe, Kazuko Sakai, Kaoru Tanaka, Hidetoshi Hayashi, Hiroyasu Kaneda, Ken Takeawa, Kiyoko Kuvata, Haruka Yamaguchi, Erina Hatashita, Kazuto Nishio, and Kazuhiro Nakagawa</td>
</tr>
<tr>
<td>6227</td>
<td>Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells</td>
<td>Warren Fiskus, Rekha Rao, Ramesh Balusu, Siddhartha Ganguly, Jianguo Tao, Eduardo Sottomayor, Uma Mudumurt, Jacqueline E. Smith, Stacey L. Hembrough, Peter Atadja, Victor E. Marquez, and Kapil Bhalala</td>
</tr>
<tr>
<td>6249</td>
<td>In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vv9V-dimensional T-cell Antitumor Cytotoxicity through ICAM-1 Engagement</td>
<td>Ismahine Benzaïd, Hannu Mönkkönen, Edith Bonnele, Jukka Mönkkönen, and Philippe Clézardin</td>
</tr>
<tr>
<td>6260</td>
<td>Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence</td>
<td>Maria T. Di Martino, Emanuela Leone, Nicola Amordio, Umberto Foresta, Marta Lionetti, Maria R. Pitarri, Maria E. Gallo Cantafio, Annamaria Gullà, Francesco Conforti, Eugenio Morelli, Vera Tomaino, Marco Rosso, Massimo Negri, Manlio Ferrarini, Michele Caraglia, Massoud A. Shamma, Nikhil C. Munshi, Kenneth C. Anderson, Antonino Neri, Pierosandro Tagliaferri, and Pierfrancesco Tassone</td>
</tr>
</tbody>
</table>

**TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-I/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles**

| 6267 | Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor | Magalie Dosset, Yann Godet, Charline Vauchy, Laurent Bezijnad, Yu Chun Lone, Christine Sedill, Christelle Liard, Emilie Levismois, Bertrand Clerc, Federico Sandoval, Etienne Daguindau, Simon Wain-Hobson, Eric Tartour, Pierre Langlade-Demoyen, Christophe Borg, and Olivier Adotévi |

**Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands**

| 6296 | Antibody-Dependent Cell-Mediated Cytotoxicity Overcomes NK Cell Resistance in MLL-Rearranged Leukemia Expressing Inhibitory KIR Ligands but Not Activating Ligands | Wing Keung Chan, May Kung Sutherland, Ying Li, Jonathan Zalevsky, Sarah Schell, and Wing Leung |
IMAGING, DIAGNOSIS, PROGNOSIS

6306 Measurement of Tumor VEGF-A Levels with 89Zr-Bevacizumab PET as an Early Biomarker for the Antiangiogenic Effect of Everolimus Treatment in an Ovarian Cancer Xenograft Model


6315 Scatter Spectroscopic Imaging Distinguishes between Breast Pathologies in Tissues Relevant to Surgical Margin Assessment

Ashley M. Laughney, Venkataraman Krishnaswamy, Elizabeth J. Rizzo, Mary C. Schwab, Richard J. Barth, Brian W. Pogue, Keith D. Paulsen, and Wendy A. Wells

See commentary p. 6083

6326 Impact of the Integrin Signaling Adaptor Protein NEDD9 on Prognosis and Metastatic Behavior of Human Lung Cancer

Shunsuke Kondo, Satoshi Iwata, Taketo Yamada, Yusuke Inoue, Hiromi Ichihara, Yoshiho Kichikawa, Tomoki Katayose, Akiko Souta-Kuribara, Hiroto Yamazaki, Osamu Hosono, Hiroshi Kawasaki, Hiroshi Tanaka, Yuichiro Hayashi, Michie Sakamoto, Kazunori Kamiya, Nam H. Dang, and Chikao Morimoto

6339 Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Long-term Survivors

Shinichi Yachida, Catherine M. White, Yoshiho Naito, Yi Zhong, Jacqueline A. Brosnan, Anne M. Macgregor-Das, Richard A. Morgan, Tyler Saunders, Daniel A. Laheru, Joseph M. Herman, Ralph H. Hruban, Alison P. Klein, Siân Jones, Victor Velculescu, Christopher L. Wolfgang, and Christine A. Iacobuzio-Donahue

6348 Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients

Janet E. Brown, Richard J. Cook, Allan Lipton, and Robert E. Coleman

CANCER THERAPY: CLINICAL

6356 Outcomes of Phase II Clinical Trials with Single-Agent Therapies in Advanced/Metastatic Non–Small Cell Lung Cancer Published between 2000 and 2009

Filip Janku, Donald A. Berry, Jing Gong, Henrique A. Parsons, David J. Stewart, and Razelle Kurzrock

6364 Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788

Jose Baselga, Alain C. Mita, Patrick Schöffski, Herlinde Dumez, Frederico Rojo, Josep Tabernero, Clifford DiLea, William Mietlowksi, Christie Low, Jerry Huang, Margaret Dugan, Kathryn Parker, Eric Walk, Allan van Oosterom, Erika Martinelli, and Chris H. Takimoto

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

6373 Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

Apostolia-Maria Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchuk, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra, Yang Ye, Sijin Wen, Donald Berry, and Razelle Kurzrock

6384 Association between VEGF Splice Isoforms and Progression-Free Survival in Metastatic Colorectal Cancer Patients Treated with Bevacizumab

David O. Bates, Paul J. Catalano, Kirsty E. Symonds, Alex H.B. Varey, Pramila Ramani, Peter J. O'Dwyer, Bruce J. Giantonio, Neal J. Meropol, Al Bowen Benson, and Steven J. Harper
ABOUT THE COVER

Replication-incompetent Sendai virus particles were injected into orthotopic prostate cancers in NOD-SCID mice on day 29 after the inoculation of human prostate cancer PC3 cells. The dual 4',6-diamidino-2-phenylindole (blue) and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (DAPI; green) staining showed that the TUNEL-positive apoptotic cells were dramatically increased in tumor regions. For details, see the article by Matsushima-Miyagi and colleagues on page 6271 of this issue.